| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angiogenesis Inhibitors | 14 | 2012 | 1248 | 1.500 |
Why?
|
| Neovascularization, Pathologic | 17 | 2012 | 1547 | 1.210 |
Why?
|
| Lung Neoplasms | 40 | 2024 | 11538 | 1.010 |
Why?
|
| Hyperoxia | 5 | 2018 | 133 | 0.940 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 24 | 2024 | 5319 | 0.870 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2014 | 528 | 0.730 |
Why?
|
| Pituitary Neoplasms | 2 | 2017 | 203 | 0.610 |
Why?
|
| Gonadotropins | 1 | 2016 | 50 | 0.570 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2016 | 156 | 0.550 |
Why?
|
| Radiosurgery | 7 | 2021 | 1330 | 0.540 |
Why?
|
| Oxygen | 4 | 2011 | 754 | 0.510 |
Why?
|
| Adenoma | 2 | 2017 | 716 | 0.500 |
Why?
|
| Vascular Endothelial Growth Factor A | 10 | 2012 | 1533 | 0.490 |
Why?
|
| Proton Therapy | 6 | 2024 | 1577 | 0.470 |
Why?
|
| Endostatins | 5 | 2007 | 48 | 0.450 |
Why?
|
| Apoptosis | 13 | 2014 | 7591 | 0.450 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2014 | 430 | 0.440 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2014 | 316 | 0.420 |
Why?
|
| Chemoradiotherapy | 8 | 2018 | 1946 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2008 | 272 | 0.410 |
Why?
|
| Quinazolines | 5 | 2012 | 923 | 0.400 |
Why?
|
| Adenocarcinoma | 16 | 2017 | 7789 | 0.400 |
Why?
|
| Proliferating Cell Nuclear Antigen | 3 | 2006 | 195 | 0.400 |
Why?
|
| bcl-X Protein | 1 | 2010 | 196 | 0.370 |
Why?
|
| Carcinoma, Small Cell | 3 | 2014 | 408 | 0.360 |
Why?
|
| Cell Nucleus | 1 | 2014 | 1620 | 0.330 |
Why?
|
| Neoplasms | 11 | 2022 | 15193 | 0.330 |
Why?
|
| Pulmonary Alveoli | 2 | 2006 | 208 | 0.320 |
Why?
|
| ErbB Receptors | 5 | 2007 | 2295 | 0.310 |
Why?
|
| Radiation Pneumonitis | 4 | 2018 | 301 | 0.310 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2012 | 355 | 0.300 |
Why?
|
| Piperidines | 3 | 2007 | 1035 | 0.300 |
Why?
|
| Antithrombins | 1 | 2007 | 74 | 0.300 |
Why?
|
| Mitochondria | 1 | 2014 | 1282 | 0.300 |
Why?
|
| Epithelial Cells | 2 | 2005 | 1818 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2020 | 10035 | 0.270 |
Why?
|
| G1 Phase | 2 | 2006 | 285 | 0.270 |
Why?
|
| Respiratory Mucosa | 1 | 2006 | 206 | 0.260 |
Why?
|
| Paclitaxel | 5 | 2017 | 1996 | 0.250 |
Why?
|
| Cell Cycle Proteins | 4 | 2014 | 2045 | 0.240 |
Why?
|
| Anesthesia, Spinal | 1 | 2004 | 18 | 0.240 |
Why?
|
| Hernia, Inguinal | 1 | 2004 | 49 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2017 | 5437 | 0.230 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2013 | 406 | 0.230 |
Why?
|
| Liver Regeneration | 1 | 2003 | 134 | 0.210 |
Why?
|
| Anesthesia, General | 1 | 2004 | 239 | 0.210 |
Why?
|
| DNA Damage | 4 | 2005 | 1954 | 0.200 |
Why?
|
| Humans | 67 | 2024 | 261506 | 0.200 |
Why?
|
| Aged | 34 | 2024 | 70117 | 0.200 |
Why?
|
| Aged, 80 and over | 23 | 2020 | 29902 | 0.200 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2021 | 14 | 0.200 |
Why?
|
| Sphenoid Sinus | 1 | 2021 | 21 | 0.200 |
Why?
|
| Neuroendoscopy | 1 | 2021 | 31 | 0.200 |
Why?
|
| Male | 46 | 2021 | 123000 | 0.190 |
Why?
|
| Cell Proliferation | 9 | 2014 | 7226 | 0.180 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2021 | 209 | 0.180 |
Why?
|
| Peptide Fragments | 6 | 2002 | 1271 | 0.180 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 14889 | 0.180 |
Why?
|
| Middle Aged | 33 | 2021 | 86204 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2012 | 4549 | 0.170 |
Why?
|
| Mice | 23 | 2018 | 34495 | 0.170 |
Why?
|
| Animals | 29 | 2018 | 59536 | 0.170 |
Why?
|
| Plasminogen | 4 | 2002 | 26 | 0.170 |
Why?
|
| Radiotherapy, Conformal | 2 | 2016 | 902 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2017 | 2231 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 7551 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 8 | 2018 | 6942 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 203 | 0.160 |
Why?
|
| Air Pollutants | 2 | 2018 | 139 | 0.160 |
Why?
|
| Sesquiterpenes | 3 | 2007 | 68 | 0.160 |
Why?
|
| Oxidative Stress | 1 | 2005 | 1129 | 0.160 |
Why?
|
| Combined Modality Therapy | 7 | 2010 | 8865 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 7 | 2013 | 5395 | 0.160 |
Why?
|
| Steroids | 1 | 2020 | 356 | 0.160 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2020 | 172 | 0.150 |
Why?
|
| Endothelium, Vascular | 5 | 2007 | 891 | 0.150 |
Why?
|
| Phosphorylation | 7 | 2014 | 4804 | 0.150 |
Why?
|
| Cost of Illness | 2 | 2016 | 498 | 0.150 |
Why?
|
| Female | 37 | 2021 | 141928 | 0.150 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 327 | 0.150 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2020 | 223 | 0.150 |
Why?
|
| Cell Line, Tumor | 10 | 2014 | 14551 | 0.150 |
Why?
|
| Radiotherapy | 2 | 2017 | 1824 | 0.150 |
Why?
|
| Mice, Nude | 10 | 2013 | 4307 | 0.150 |
Why?
|
| Thoracic Neoplasms | 1 | 2020 | 337 | 0.150 |
Why?
|
| Cell Division | 6 | 2006 | 2489 | 0.140 |
Why?
|
| Antineoplastic Agents | 8 | 2017 | 14289 | 0.140 |
Why?
|
| Hypopituitarism | 1 | 2016 | 33 | 0.140 |
Why?
|
| Hepatectomy | 1 | 2003 | 1011 | 0.140 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2018 | 2104 | 0.140 |
Why?
|
| Cyclohexanes | 3 | 2007 | 38 | 0.140 |
Why?
|
| Blotting, Western | 6 | 2013 | 3536 | 0.140 |
Why?
|
| Thyroxine | 1 | 2016 | 116 | 0.140 |
Why?
|
| Pneumonectomy | 1 | 2021 | 831 | 0.140 |
Why?
|
| Re-Irradiation | 1 | 2017 | 163 | 0.140 |
Why?
|
| Receptors, Interleukin-8B | 2 | 2012 | 56 | 0.130 |
Why?
|
| Lung | 2 | 2013 | 3151 | 0.130 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2017 | 304 | 0.130 |
Why?
|
| Hydrocortisone | 1 | 2016 | 388 | 0.130 |
Why?
|
| Cell Death | 2 | 2010 | 671 | 0.130 |
Why?
|
| Adult | 23 | 2021 | 77950 | 0.130 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2014 | 68 | 0.120 |
Why?
|
| Europe | 1 | 2016 | 649 | 0.120 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2014 | 3552 | 0.120 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2014 | 32 | 0.120 |
Why?
|
| Radiation Tolerance | 3 | 2007 | 629 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2024 | 3890 | 0.120 |
Why?
|
| Carboplatin | 1 | 2017 | 823 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2005 | 3343 | 0.120 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 205 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2019 | 312 | 0.120 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 133 | 0.120 |
Why?
|
| Mortality | 1 | 2016 | 343 | 0.120 |
Why?
|
| Retroviridae | 1 | 2014 | 332 | 0.120 |
Why?
|
| Esophagitis | 1 | 2014 | 202 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2013 | 852 | 0.110 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2015 | 303 | 0.110 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 174 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 5 | 2004 | 223 | 0.110 |
Why?
|
| Time Factors | 8 | 2021 | 12926 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 2 | 2018 | 1350 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 2216 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 2018 | 786 | 0.110 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2012 | 33 | 0.110 |
Why?
|
| Cognition | 1 | 2018 | 968 | 0.110 |
Why?
|
| Patient Selection | 1 | 2020 | 2055 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2007 | 11965 | 0.110 |
Why?
|
| Inflammation | 3 | 2014 | 2522 | 0.110 |
Why?
|
| Neurosurgical Procedures | 1 | 2017 | 609 | 0.100 |
Why?
|
| Salvage Therapy | 2 | 2018 | 2054 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Treatment Outcome | 13 | 2022 | 32848 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 257 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 362 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 315 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2017 | 1987 | 0.100 |
Why?
|
| DNA Ligases | 1 | 2011 | 63 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2012 | 639 | 0.100 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 13658 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2021 | 12873 | 0.100 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2010 | 72 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 3719 | 0.100 |
Why?
|
| Transfection | 2 | 2014 | 2944 | 0.100 |
Why?
|
| Mustard Compounds | 1 | 2010 | 8 | 0.100 |
Why?
|
| Etoposide | 1 | 2013 | 870 | 0.100 |
Why?
|
| Cell Survival | 2 | 2010 | 3045 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 545 | 0.090 |
Why?
|
| Phenylpropionates | 1 | 2010 | 19 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2010 | 376 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2012 | 305 | 0.090 |
Why?
|
| Young Adult | 6 | 2021 | 21445 | 0.090 |
Why?
|
| Camptothecin | 1 | 2013 | 517 | 0.090 |
Why?
|
| Retrospective Studies | 14 | 2024 | 37905 | 0.090 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2007 | 95 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 367 | 0.090 |
Why?
|
| Prognosis | 7 | 2020 | 21713 | 0.090 |
Why?
|
| Radiotherapy Dosage | 5 | 2017 | 3842 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2005 | 448 | 0.090 |
Why?
|
| Proportional Hazards Models | 5 | 2018 | 4988 | 0.090 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2010 | 275 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2015 | 620 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 987 | 0.090 |
Why?
|
| Collagen | 2 | 2002 | 752 | 0.090 |
Why?
|
| Epidermal Growth Factor | 2 | 2007 | 423 | 0.080 |
Why?
|
| Survival Rate | 8 | 2018 | 12221 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2015 | 732 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2012 | 428 | 0.080 |
Why?
|
| Metformin | 1 | 2012 | 378 | 0.080 |
Why?
|
| Endothelium | 3 | 2004 | 158 | 0.080 |
Why?
|
| DNA Repair | 2 | 2014 | 1872 | 0.080 |
Why?
|
| Thrombosis | 1 | 2015 | 781 | 0.080 |
Why?
|
| Flow Cytometry | 2 | 2007 | 3033 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 586 | 0.080 |
Why?
|
| Haplotypes | 1 | 2010 | 856 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2005 | 726 | 0.080 |
Why?
|
| Recombinant Proteins | 5 | 2004 | 2927 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 719 | 0.080 |
Why?
|
| Probability | 2 | 2012 | 866 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2012 | 3821 | 0.070 |
Why?
|
| Mice, Inbred CBA | 1 | 2007 | 78 | 0.070 |
Why?
|
| Angiogenic Proteins | 1 | 2007 | 37 | 0.070 |
Why?
|
| Sex Characteristics | 1 | 2009 | 417 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2576 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2014 | 1664 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2010 | 1493 | 0.070 |
Why?
|
| Animals, Newborn | 2 | 2011 | 1338 | 0.070 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2003 | 35 | 0.070 |
Why?
|
| Endothelial Cells | 3 | 2007 | 1048 | 0.070 |
Why?
|
| DNA | 1 | 2014 | 2693 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2006 | 5710 | 0.070 |
Why?
|
| Immunotherapy | 3 | 2024 | 3341 | 0.070 |
Why?
|
| HMGA2 Protein | 1 | 2005 | 19 | 0.070 |
Why?
|
| Organophosphorus Compounds | 1 | 2006 | 101 | 0.070 |
Why?
|
| Neuropilin-1 | 1 | 2005 | 40 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2021 | 5542 | 0.070 |
Why?
|
| Cisplatin | 1 | 2013 | 2432 | 0.070 |
Why?
|
| Stilbenes | 1 | 2006 | 86 | 0.070 |
Why?
|
| Cell Count | 1 | 2006 | 508 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2013 | 2307 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2007 | 587 | 0.060 |
Why?
|
| Uteroglobin | 1 | 2005 | 54 | 0.060 |
Why?
|
| Biomarkers | 3 | 2014 | 5047 | 0.060 |
Why?
|
| Smoking | 2 | 2012 | 2440 | 0.060 |
Why?
|
| Interleukin-8 | 2 | 2004 | 519 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 2173 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 1082 | 0.060 |
Why?
|
| Protein Conformation | 1 | 2007 | 1258 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 15862 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 694 | 0.060 |
Why?
|
| Total Quality Management | 1 | 2004 | 34 | 0.060 |
Why?
|
| Risk | 3 | 2013 | 1972 | 0.060 |
Why?
|
| Lidocaine | 1 | 2004 | 76 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1054 | 0.060 |
Why?
|
| Anesthetics, Intravenous | 1 | 2004 | 73 | 0.060 |
Why?
|
| Laryngeal Masks | 1 | 2004 | 75 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 4971 | 0.060 |
Why?
|
| Lung Injury | 1 | 2005 | 131 | 0.060 |
Why?
|
| Mink | 1 | 2002 | 8 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2003 | 43 | 0.060 |
Why?
|
| Risk Factors | 6 | 2018 | 17523 | 0.060 |
Why?
|
| Edema | 1 | 2005 | 267 | 0.060 |
Why?
|
| Emergency Treatment | 1 | 2004 | 105 | 0.060 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 74 | 0.060 |
Why?
|
| Comet Assay | 1 | 2002 | 59 | 0.050 |
Why?
|
| Corneal Neovascularization | 1 | 2002 | 14 | 0.050 |
Why?
|
| Age Factors | 2 | 2016 | 5377 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2006 | 703 | 0.050 |
Why?
|
| Fibrosarcoma | 1 | 2003 | 135 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 661 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1945 | 0.050 |
Why?
|
| Homozygote | 1 | 2005 | 717 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 31252 | 0.050 |
Why?
|
| Microcirculation | 1 | 2003 | 200 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 2314 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6207 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10331 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2004 | 257 | 0.050 |
Why?
|
| Patient Admission | 1 | 2003 | 220 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 4892 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2003 | 220 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2006 | 2074 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2014 | 2947 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2017 | 833 | 0.050 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2002 | 292 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2003 | 351 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 717 | 0.050 |
Why?
|
| Pyrroles | 1 | 2004 | 576 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 7548 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 3230 | 0.050 |
Why?
|
| Adrenal Cortex | 1 | 2020 | 35 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 53 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2020 | 95 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 4143 | 0.050 |
Why?
|
| Disease Progression | 4 | 2016 | 6682 | 0.050 |
Why?
|
| Sex Factors | 2 | 2017 | 2139 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2010 | 1165 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2004 | 953 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2005 | 686 | 0.040 |
Why?
|
| Angiostatins | 4 | 2002 | 7 | 0.040 |
Why?
|
| Dyspnea | 1 | 2022 | 416 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 2054 | 0.040 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2004 | 157 | 0.040 |
Why?
|
| Genotype | 3 | 2012 | 4109 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 2020 | 188 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 544 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 10001 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 1678 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 3168 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 3639 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2005 | 3005 | 0.040 |
Why?
|
| Radiation Injuries | 2 | 2016 | 1411 | 0.040 |
Why?
|
| Receptor, Insulin | 1 | 1998 | 97 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2018 | 86 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 665 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2004 | 1145 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 2 | 2006 | 5061 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 1450 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 319 | 0.040 |
Why?
|
| Kringles | 1 | 1996 | 8 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2017 | 219 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2011 | 4821 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 1130 | 0.040 |
Why?
|
| United Kingdom | 1 | 2017 | 257 | 0.040 |
Why?
|
| Neoplasms, Experimental | 2 | 1997 | 750 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 2588 | 0.040 |
Why?
|
| Adenoma, Islet Cell | 1 | 1996 | 27 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 478 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2018 | 9244 | 0.030 |
Why?
|
| Oligopeptides | 1 | 1998 | 429 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 2370 | 0.030 |
Why?
|
| Interphase | 2 | 2005 | 145 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2006 | 4078 | 0.030 |
Why?
|
| Enzyme Activation | 3 | 2005 | 1764 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1998 | 577 | 0.030 |
Why?
|
| Learning | 1 | 2018 | 403 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2003 | 1616 | 0.030 |
Why?
|
| Interferon Type I | 1 | 1996 | 250 | 0.030 |
Why?
|
| Protons | 1 | 2017 | 473 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 1374 | 0.030 |
Why?
|
| Minocycline | 1 | 1996 | 182 | 0.030 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2004 | 74 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 4367 | 0.030 |
Why?
|
| Lisinopril | 1 | 2013 | 24 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 2518 | 0.030 |
Why?
|
| Valsartan | 1 | 2013 | 38 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2021 | 1959 | 0.030 |
Why?
|
| Gene Dosage | 2 | 2007 | 829 | 0.030 |
Why?
|
| Pain Management | 1 | 2019 | 668 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 1226 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 1021 | 0.030 |
Why?
|
| Liver | 1 | 2003 | 2961 | 0.030 |
Why?
|
| Valine | 1 | 2013 | 176 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 3251 | 0.030 |
Why?
|
| Tetrazoles | 1 | 2013 | 106 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 795 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 252 | 0.030 |
Why?
|
| Heart Atria | 1 | 2015 | 352 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2004 | 3518 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 2 | 2004 | 310 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 756 | 0.030 |
Why?
|
| DNA Ligase ATP | 1 | 2011 | 51 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 751 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2011 | 79 | 0.030 |
Why?
|
| Receptors, Interleukin-8 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2016 | 1014 | 0.020 |
Why?
|
| Necrosis | 1 | 2013 | 580 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1656 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2004 | 6869 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 2011 | 119 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1217 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 2005 | 1519 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1998 | 1756 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 1008 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2010 | 94 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 1546 | 0.020 |
Why?
|
| Incidence | 1 | 2020 | 5673 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1077 | 0.020 |
Why?
|
| Fatigue | 1 | 2016 | 1239 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 1085 | 0.020 |
Why?
|
| Heart Failure | 1 | 2003 | 2516 | 0.020 |
Why?
|
| Induction Chemotherapy | 1 | 2012 | 669 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2011 | 434 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2012 | 5112 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1301 | 0.020 |
Why?
|
| Child | 2 | 2021 | 29154 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2010 | 4844 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 999 | 0.020 |
Why?
|
| Esophagectomy | 1 | 2012 | 911 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 770 | 0.020 |
Why?
|
| Pain | 1 | 2016 | 1658 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 34 | 0.020 |
Why?
|
| Purines | 1 | 2007 | 273 | 0.020 |
Why?
|
| Digestive System | 1 | 2006 | 114 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2007 | 201 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 2466 | 0.020 |
Why?
|
| Cattle | 2 | 1997 | 783 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 363 | 0.020 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2005 | 76 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1331 | 0.020 |
Why?
|
| Weight Loss | 1 | 2009 | 627 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 4938 | 0.020 |
Why?
|
| Capecitabine | 1 | 2006 | 388 | 0.020 |
Why?
|
| Models, Biological | 2 | 2004 | 3254 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 3981 | 0.020 |
Why?
|
| Nurse Clinicians | 1 | 2004 | 5 | 0.020 |
Why?
|
| Emergency Nursing | 1 | 2004 | 9 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2005 | 187 | 0.020 |
Why?
|
| Nurse's Role | 1 | 2004 | 42 | 0.010 |
Why?
|
| Nova Scotia | 1 | 2003 | 3 | 0.010 |
Why?
|
| Collagen Type XVIII | 1 | 2002 | 17 | 0.010 |
Why?
|
| Fluorophotometry | 1 | 2002 | 34 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 1544 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 1618 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2002 | 51 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 2488 | 0.010 |
Why?
|
| E-Selectin | 1 | 2002 | 103 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2012 | 2669 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 669 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 212 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 121 | 0.010 |
Why?
|
| Bevacizumab | 1 | 2006 | 938 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 664 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 197 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2007 | 2292 | 0.010 |
Why?
|
| Triage | 1 | 2004 | 252 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2006 | 690 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 6009 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2005 | 1643 | 0.010 |
Why?
|
| Lymphokines | 1 | 2002 | 272 | 0.010 |
Why?
|
| Lasers | 1 | 2002 | 198 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 1021 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2002 | 266 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2002 | 314 | 0.010 |
Why?
|
| Medical Records | 1 | 2003 | 415 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2006 | 1944 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2330 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 242 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 15694 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2002 | 875 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 810 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1997 | 4233 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2005 | 1070 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2012 | 9180 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2005 | 1090 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2006 | 1353 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 3472 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1997 | 6089 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 1382 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2006 | 1299 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2002 | 1290 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2004 | 712 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 2315 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2004 | 1274 | 0.010 |
Why?
|
| Histones | 1 | 2005 | 1466 | 0.010 |
Why?
|
| Spodoptera | 1 | 1997 | 63 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 7222 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 1998 | 111 | 0.010 |
Why?
|
| Baculoviridae | 1 | 1997 | 86 | 0.010 |
Why?
|
| Protein Sorting Signals | 1 | 1997 | 44 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 821 | 0.010 |
Why?
|
| Cornea | 1 | 2002 | 638 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 1998 | 161 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 1823 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 1879 | 0.010 |
Why?
|
| Tyrosine | 1 | 1998 | 498 | 0.010 |
Why?
|
| Length of Stay | 1 | 2003 | 1900 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2004 | 1148 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2004 | 1162 | 0.010 |
Why?
|
| Protein Folding | 1 | 1996 | 281 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 4758 | 0.010 |
Why?
|
| S Phase | 1 | 1996 | 281 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 997 | 0.010 |
Why?
|
| United States | 1 | 2012 | 15433 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 1996 | 345 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2004 | 2403 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 6295 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1997 | 1694 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1997 | 1555 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 4757 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 5270 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1998 | 5637 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 7702 | 0.000 |
Why?
|